The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Systemic Histoplasmosis: A 15-Year Retrospective Institutional Review of 111 Patients
Abstract
To our knowledge, an institutional review of systemic histoplasmosis has not been conducted in the United States since the major outbreaks in Indianapolis in 1978-4982. We conducted a retrospective review of all patients with systemic histoplasmosis diagnosed at Mayo Clinic over a 15-year period. The case definitions employed were based on an international consensus statement by the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group (EORTC/IFICG) and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (MSG). One hundred eleven patients with systemic histoplasmosis were identified between January 1, 1991, and December 31, 2005. Of these, 78 patients had disseminated histoplasmosis and 55 patients had Histoplasma capsulatum fungemia. The mean age of patients was 55 years, 66% were male, and 98% were white. Fifty-nine percent of patients were immunocompromised. Fever was the most frequently reported symptom (63%), followed by respiratory complaints (43%) and weight loss (37%). The peripheral white blood cell count was <3000 cells/mm in 28%, hemoglobin was <10 g/dL in 29%, and platelet count was <150,000 cells/mm in 41% of patients. Liver enzymes were elevated (alanine aminotransferase >60 U/L in 39%, aspartate aminotransferase >60 U/L in 27%), alkaline phosphatase was >200 U/L in 55%, and albumin was <3.5 g/dL in 70%. Serologic and histopathologic examinations were each positive in 75% of cases, Histoplasma urine antigen screening was positive in 80%, and H. capsulatum was culture positive in 84%. Forty-seven percent of patients were sequentially treated with an amphotericin B-containing product followed by itraconazole, 31% received itraconazole alone, and 7% received an amphotericin B-containing product only. Another 13% of patients did not receive antifungal treatment, and the remaining 2% did not have treatment data available. Sixty percent of patients required hospitalization, and in hospital mortality was 6% with a median survival time of 61 days. The relapse rate was 9%, with a median relapse-free survival of 857 days. Systemic histoplasmosis should be suspected in patients who have lived in endemic areas with fever, bone marrow suppression, and elevated hepatic enzymes, particularly if they are immunocompromised. Evaluation including a combination of Histoplasma serologic screening, urine antigen assay, and fungal culture will secure the diagnosis in most cases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Infectious Diseases Society of America
Enders, J. F. (1969) · Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,286
Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists
Wallis, R. S., Broder, M. S., Wong, J. Y., Hanson, M. E., & Beenhouwer, D. O. (2004) · Clinical Infectious Diseases · doi:10.1086/383317 · Cited by 977
WHEAT, L. J., CONNOLLY-STRINGFIELD, P. A., BAKER, R. L., CURFMAN, M. F., EADS, M. E., ISRAEL, K. S., NORRIS, S. A., WEBB, D. H., & ZECKEL, M. L. (1990) · Medicine · doi:10.1097/00005792-199011000-00004 · Cited by 651
Disseminated Histoplasmosis: Clinical and Pathologic Correlations
GOODWIN, R. A., SHAPIRO, J. L., THURMAN, G. H., THURMAN, S. S., & DES PREZ, R. M. (1980) · Medicine · doi:10.1097/00005792-198001000-00001 · Cited by 620
Practice Guidelines for the Management of Patients with Histoplasmosis
Wheat, J., Sarosi, G., McKinsey, D., Hamill, R., Bradsher, R., Johnson, P., Loyd, J., & Kauffman, C. (2000) · Clinical Infectious Diseases · doi:10.1086/313752 · Cited by 382
Crum, N. F., Lederman, E. R., Stafford, C. M., Parrish, J. S., & Wallace, M. R. (2004) · Medicine · doi:10.1097/01.md.0000126762.91040.fd · Cited by 265
Histoplasmosis after Treatment with Anti–Tumor Necrosis Factor-α Therapy
Wood, K. L., Hage, C. A., Knox, K. S., Kleiman, M. B., Sannuti, A., Day, R. B., Wheat, L. J., & Twigg, H. L. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200206-563oc · Cited by 237
Rosenstein, N. E., Emery, K. W., Werner, S. B., Kao, A., Johnson, R., Rogers, D., Vugia, D., Reingold, A., Talbot, R., Plikaytis, B. D., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/319203 · Cited by 232
Wheat, L. J., & Kauffman, C. A. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(02)00039-9 · Cited by 224
Risk Factors for Disseminated or Fatal Histoplasmosis: Analysis of a Large Urban Outbreak
WHEAT, L. J., SLAMA, T. G., NORTON, J. A., KOHLER, R. B., EITZEN, H. E., FRENCH, M. L. V., & SATHAPATAYAVONGS, B. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-2-159 · Cited by 196
Cited by
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Wheat, L. J., Azar, M. M., Bahr, N. C., Spec, A., Relich, R. F., & Hage, C. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.009 · Cited by 329
Emerging and reemerging fungal infections
Lockhart, S. R., & Guarner, J. (2019) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2019.04.010 · Cited by 169
Metadata
- Authors
- Assi, M. A., Sandid, M. S., Baddour, L. M., Roberts, G. D., & Walker, R. C.
- Venue
- Medicine
- Published
- 2007-05
- Volume
- 86
- Issue
- 3
- Pages
- 162-169
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W1981128005
- Cited by
- 261
- References
- 27
- FWCI
- 5.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Systemic Histoplasmosis: A 15-Year Retrospective Institutional Review of 111 Patients. https://app.cochat.ai/papers/10.1097/md.0b013e3180679130
- The paper
- Assi, M. A., Sandid, M. S., Baddour, L. M., Roberts, G. D., & Walker, R. C. (2007). Systemic Histoplasmosis: A 15-Year Retrospective Institutional Review of 111 Patients. Medicine. https://doi.org/10.1097/md.0b013e3180679130
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.